TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

MSD partners LaNova Medicines on a PD-1 and VEGF targeting candidate for cancer, a potential replacement for its top-seller Keytruda.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, primarily due to its dense, desmoplastic and immunosuppressive tumor microenvironment (TME) that hinders the efficacy of ...

The conversion of acetylcholine binding into ion conduction across the membrane is becoming more clearly understood in terms of the structure of the receptor and its transitions. A high-resolution ...

Molecular glues, tiny molecules that connect one protein to another, are promising targets for pharmaceutical research. By ...

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...